• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Innovus Pharmaceuticals acquires fluticasone nasal spray

Innovus Pharmaceuticals has announced that the acquisition of Novalere FP and its FlutiCare fluticasone propionate nasal spray. According to documents related to the merger filed with the US Securities and Exchange Commission (SEC), Novalere FP filed an ANDA for the product with the FDA in November 2014. The company says that it expects that the ANDA “may be approved by the end of 2015 or in the first half of 2016.”

Products currently marketed by Innovus include a hemorrhoid cream, an arthritis cream, and several “sexual dysfunction treatments.”

Innovus Pharma President and CEO Bassam Damaj commented, “This transaction is transformative for Innovus. The nasal steroid market in the United States is undergoing a revolution with the expected launch of fluticasone propionate nasal spray in the US, transitioning this market to an Over-the-Counter (“OTC”) market. We expect to play a significant role in this market and hopefully in other markets throughout the world by proposing to consumers an alternative product using the product form they have been used to as a prescription medicine for years. Access to the same product form for consumers may support better compliance and better outcome for consumers; many of them use the nasal spray on a continuous basis because they have a chronic condition.”

Damaj continued, “There is significant synergy between the potential of FlutiCare and the growing infrastructure Innovus Pharma is building both domestically and internationally. We expect that our capabilities and infrastructure together with the investor support will take Innovus to the next level as a growing profitable OTC company.”

Read the Innovus Pharmaceuticals press release.

Share

published on February 6, 2015

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews